New Delhi: Sun Pharmaceutical Industries on Thursday said it is gearing up to introduce Merck Sharp Dohme (MSD) and Ridgeback's molnupiravir pill, used for the treatment of Covid-19, under the brand name ‘Molxvir’ in India.
The Drugs Controller General of India (DCGI) is currently reviewing clinical data of molnupiravir for the treatment of COVID-19 in adults in India.
Earlier this year, Sun Pharma had signed a non-exclusive voluntary licensing agreement with MSD to manufacture and supply molnupiravir in India and to over 100 low- and middle-income countries.
Molnupiravir is the first oral antiviral approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of mild-to-moderate COVID-19 in adults.